Tekla Operating Margin from 2010 to 2026

HQL Stock  USD 17.06  0.02  0.12%   
Tekla Life Operating Profit Margin yearly trend continues to be quite stable with very little volatility. Operating Profit Margin may rise above 0.94 this year.
Check Tekla Life financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tekla Life's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.1 M, Interest Expense of 0.0 or Total Revenue of 104.3 M, as well as many indicators such as Price To Sales Ratio of 5.66, Dividend Yield of 0.11 or PTB Ratio of 0.7. Tekla financial statements analysis is a perfect complement when working with Tekla Life Valuation or Volatility modules.
  
Build AI portfolio with Tekla Stock
Check out the analysis of Tekla Life Correlation against competitors.
Historical Operating Margin data for Tekla Life serves as a key indicator of operational performance and financial stability. Tracking changes in this metric over time helps investors spot emerging trends before they become obvious, providing an edge in assessing whether Tekla Life Sciences represents a compelling investment opportunity.

Latest Tekla Life's Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Tekla Life Sciences over the last few years. It is Tekla Life's Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tekla Life's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (3.47) %10 Years Trend
Slightly volatile
   Operating Profit Margin   
       Timeline  

Tekla Operating Margin Regression Statistics

Arithmetic Mean(0.99)
Coefficient Of Variation(248.56)
Mean Deviation1.98
Median(0.60)
Standard Deviation2.45
Sample Variance6.02
Range9.2837
R-Value0.65
Mean Square Error3.71
R-Squared0.42
Significance0
Slope0.32
Total Sum of Squares96.32

Tekla Operating Margin History

2026 0.94
2025 0.89
2024 0.99
2023 0.98
2022 -0.13
2021 -3.28
2020 1.43

About Tekla Life Financial Statements

Tekla Life investors utilize fundamental indicators, such as Operating Margin, to predict how Tekla Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States. Tekla Life operates under Asset Management classification in the United States and is traded on New York Stock Exchange.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Tekla Life Sciences is a strong investment it is important to analyze Tekla Life's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tekla Life's future performance. For an informed investment choice regarding Tekla Stock, refer to the following important reports:
Check out the analysis of Tekla Life Correlation against competitors.
You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. Market participants price Tekla higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tekla Life assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
2.594
Dividend Share
1.82
Earnings Share
2.79
Revenue Per Share
0.065
Quarterly Revenue Growth
(0.70)
Tekla Life Sciences's market price often diverges from its book value, the accounting figure shown on Tekla's balance sheet. Smart investors calculate Tekla Life's intrinsic value—its true economic worth—which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Tekla Life's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.